All In Biotech

NDA 021468 · Takeda Pharms USA

Fosrenol

Lanthanum Carbonate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Aug 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Oct 26, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

44

13 Phase 3, 0 recruiting

FAERS reports

5,132

4,599 serious, 1,612 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 15, 2025.

LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )

Mechanism: LANTHANUM CARBONATE is a phosphate binder that reduces absorption of phosphate by forming insoluble lanthanum phosphate complexes that pass through the GI tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 26, 2004 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
4 products under this application
  • FOSRENOL · LANTHANUM CARBONATE EQ 500MG BASE · TABLET, CHEWABLE, ORAL · Prescription · TE AB
  • FOSRENOL · LANTHANUM CARBONATE EQ 750MG BASE · TABLET, CHEWABLE, ORAL · Prescription · TE AB
  • FOSRENOL · LANTHANUM CARBONATE EQ 250MG BASE · TABLET, CHEWABLE, ORAL · Discontinued
  • FOSRENOL · LANTHANUM CARBONATE EQ 1GM BASE · TABLET, CHEWABLE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lanthanum Carbonate" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death679
  • nausea504
  • vomiting492
  • constipation386
  • sepsis381
  • abdominal pain375
  • off label use351
  • general physical health deterioration348
  • abdominal distension320
  • hyponatraemia311
  • multiple organ dysfunction syndrome300
  • anaemia297

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200568
200687
200776
2008112
2009296
2010496
2011309
2012290
2013214
2014202
2015254
2016279
2017284
2018297
2019258
2020269
2021329
2022273
2023218
2024209
2025169
2026143

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fosrenol (Lanthanum Carbonate)

2024 spending

$5.3M

Beneficiaries

1,090

3,262 claims

Per beneficiary

$4,861

$11.44 per unit

View as table
YearSpending
2020$6,656,274
2021$5,669,795
2022$5,242,536
2023$5,765,884
2024$5,298,907

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 113 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.